Evaluation of rare diseases policy performance of oecd countries using mcdm methods

dc.authoridPak Güre, Merve Deniz/0000-0001-7060-3729
dc.authorscopusid57224970706
dc.authorscopusid57224967364
dc.authorwosidPak Güre, Merve Deniz/R-2064-2016
dc.authorwosidInce, Ozgur/KDO-4600-2024
dc.contributor.authorInce, Ozgur
dc.contributor.authorGure, Merve Deniz Pak
dc.date.accessioned2024-05-25T11:42:46Z
dc.date.available2024-05-25T11:42:46Z
dc.date.issued2021
dc.departmentOkan Universityen_US
dc.department-temp[Ince, Ozgur] Istanbul Okan Univ, Hlth Intuit Management, Istanbul, Turkey; [Gure, Merve Deniz Pak] Baskent Univ, Social Work, Ankara, Turkeyen_US
dc.descriptionPak Güre, Merve Deniz/0000-0001-7060-3729;en_US
dc.description.abstractObjectives: Rare diseases affect less than one out of every 2.000 people, which means they are much less visible in the general population than common diseases. It has several negative consequences for both patients and healthcare systems. Because of this negative effect, healthcare programs and policies must be well-structured. Nonetheless, countries' efforts in this area should be assessed to ensure effectiveness. The aim of this study is to assess the policy performance of 18 OECD countries in terms of rare diseases using health policy indicators. Methods: The outcomes of rare disease policy are identified using multi-objective optimization based on ratio analysis, complex proportional assessment, and technique for order preference by similarity to ideal solution methods, which are among the most efficient selection and ranking methods. Results: Germany, France, and the Netherlands are among the countries with the strongest rare disease policies. Latvia, Greece, and Turkey are among the lowest-performing countries in the ranking. Conclusions: Performance evaluation studies for service delivery and policy arrangements in the field of rare diseases are necessary.en_US
dc.identifier.citation3
dc.identifier.doi10.1016/j.hlpt.2021.100537
dc.identifier.issn2211-8837
dc.identifier.issue3en_US
dc.identifier.scopus2-s2.0-85108827351
dc.identifier.scopusqualityQ1
dc.identifier.urihttps://doi.org/10.1016/j.hlpt.2021.100537
dc.identifier.urihttps://hdl.handle.net/20.500.14517/1635
dc.identifier.volume10en_US
dc.identifier.wosWOS:000696997100002
dc.identifier.wosqualityQ1
dc.language.isoenen_US
dc.publisherElsevier Sci Ltden_US
dc.relation.publicationcategoryMakale - Uluslararası Hakemli Dergi - Kurum Öğretim Elemanıen_US
dc.rightsinfo:eu-repo/semantics/closedAccessen_US
dc.subjectRare Diseasesen_US
dc.subjectHealth Policyen_US
dc.subjectPerformance Evaluationen_US
dc.subjectMulti-Criteria Decision Making Methodsen_US
dc.titleEvaluation of rare diseases policy performance of oecd countries using mcdm methodsen_US
dc.typeArticleen_US
dspace.entity.typePublication

Files